Abstract
Although the identification and develop ment of highly immunogenic antigens often seems to be the key step in the creation of new and more effective vaccines, their formulation into stable prophylactic medicines, often in the presence of adjuvants to boost immune responses, can be an equally important challenge. This transformation of molecules into medicines is, however, often a difficult process due to the molecular complexity of most vaccines as well as some controversy over the degree to which vaccines can be treated
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
